Abstract: Objective To evaluate efficacy and safety of glucocorticoid (GC) with non-bioartificial liver support system (NBLS) in the treatment of severe drug-induced liver injury (DILI). Methods In the retrospective study, 96 cases with severe DILI who had underwent the treatment of GC combined NBLS in our hospital from January 2008 to December 2015 were enrolled. Treatment, blood routine, liver functions, and so on, were recorded. The efficacy and complications of GC combined with NBLS in treating severe DILI were observed.Results Treatment of GC combined with NBLS was effective in 84 cases (87.5%). Levels of red blood cell (RBC) (4.22±0.70)×10⁹/L and hemoglobin (Hb) (127.88±22.99) g/L were significantly higher at baseline than those after treatment (P<0.05). Levels of alanine aminotransferase (ALT) (145.48±158.94) U/L, aspartate amino transferase (AST)(98.06±69.26) U/L, total bilirubin (TBil) (165.10±124.21) μmol/L bilirubin tra, direct bilirubin (DBil) (130.66±89.46) μmol/L, indirect bilirubin (IBil) (35.43±37.48) μmol/L, albumin (Alb) (41.12±30.93) g/L and alkaline phosphatase (ALP) (178.64±119.65) U/L were significantly improved compared to those before treatment (P<0.05). However, levels of blood urea nitrogen (BUN) (5.61±2.59) mmol/L and cre-recombinase (Cre) (61.00±14.36) μmol/L in renal function were significantly higher after treatment (P<0.05). No significant difference was observed in the level of prothrombin time (PT) and plasma thromboplastin antecedent (PTA) (P>0.05). Conclusion The treatment of GC with NBLS showed satisfactory effectiveness and safety for severe DILI, which could ameliorate the disease progression, reduce total incidence of liver failure and improve the prognosis.

Key words: Drug-induced liver injury, Severe, Glucocorticoid non-bioartificial liver support system, Efficacy, Safety